Search research articles
Contact Us
Filters
Showing results (71-80 of 158) with videos related to
Page
of 16
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network
Massimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
Simona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Haematologica
|
March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
Francesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Leukemia
|
June 20, 2020
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
Massimo Breccia, Elisabetta Abruzzese, Monica Bocchia, et al.
Blood
|
February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Fausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Blood
|
October 27, 2009
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
Roberto M Lemoli, Valentina Salvestrini, Elisa Bianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
Francesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Annals of Hematology
|
October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
Mario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.
Frontiers in Oncology
|
September 12, 2025
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial
Fabio Efficace, Laura Cannella, Isabella Capodanno, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 158) with videos related to
Sort By:
Page
of 16
Clinical Lymphoma, Myeloma & Leukemia
|
September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network
Massimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
Simona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Haematologica
|
March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
Francesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Leukemia
|
June 20, 2020
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
Massimo Breccia, Elisabetta Abruzzese, Monica Bocchia, et al.
Blood
|
February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Fausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Blood
|
October 27, 2009
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
Roberto M Lemoli, Valentina Salvestrini, Elisa Bianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
Francesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Annals of Hematology
|
October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
Mario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.
Frontiers in Oncology
|
September 12, 2025
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial
Fabio Efficace, Laura Cannella, Isabella Capodanno, et al.
Page
of 16